Dana B Gal1,2, Natalie Deuitch3, Sandra Soo Jin Lee4, Rosalie Tang Simon2, Danton S Char3,5. 1. Division of Pediatric Cardiology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA. 2. Lucile Packard Children's Hospital Stanford, Palo Alto, CA. 3. Center for Biomedical Ethics, Stanford University School of Medicine, Palo Alto, CA. 4. Division of Ethics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY. 5. Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, CA.
Abstract
OBJECTIVES: Through improving diagnostics and prognostics genomic sequencing promises to significantly impact clinical decisions for children with critical cardiac disease. Little is known about how families of children with critical cardiac disease perceive the impact of genomic sequencing on clinical care choices. DESIGN: Qualitative interview study. SETTING: A high-volume, tertiary pediatric heart center. SUBJECTS: Families of children with critical cardiac disease. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thematic analysis of interview response content. Thirty-five families were interviewed. Three themes emerged: 1) benefits versus challenges of having genomic sequencing results, and 2) fears of clinical applications of genomic sequencing, and 3) nonclinical fears related to genomic sequencing. Participants struggled with perceived uses of genomic sequencing-derived knowledge. They described comfort in foreknowledge of their child's likely disease course but articulated significant apprehension around participating in care decisions with limited knowledge of genomic sequencing, genomic sequencing uses to inform clinical resource rationing decisions, and genomic sequencing uses by third parties impacting financial pressures families experience caring for a child with critical cardiac disease. CONCLUSIONS: Families' perceptions of genomic sequencing uses in critical cardiac disease appear to strain their overall trust in the health system. Erosion of trust is concerning because the potential of genomic sequencing in critical cardiac disease will be unrealized if families are unwilling to undergo genomic sequencing, let alone to participate in the ongoing research needed to link genomic sequencing variants to clinical outcomes. Our findings may have implications for genomic sequencing use in children with other critical, high-acuity diseases.
OBJECTIVES: Through improving diagnostics and prognostics genomic sequencing promises to significantly impact clinical decisions for children with critical cardiac disease. Little is known about how families of children with critical cardiac disease perceive the impact of genomic sequencing on clinical care choices. DESIGN: Qualitative interview study. SETTING: A high-volume, tertiary pediatric heart center. SUBJECTS: Families of children with critical cardiac disease. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Thematic analysis of interview response content. Thirty-five families were interviewed. Three themes emerged: 1) benefits versus challenges of having genomic sequencing results, and 2) fears of clinical applications of genomic sequencing, and 3) nonclinical fears related to genomic sequencing. Participants struggled with perceived uses of genomic sequencing-derived knowledge. They described comfort in foreknowledge of their child's likely disease course but articulated significant apprehension around participating in care decisions with limited knowledge of genomic sequencing, genomic sequencing uses to inform clinical resource rationing decisions, and genomic sequencing uses by third parties impacting financial pressures families experience caring for a child with critical cardiac disease. CONCLUSIONS: Families' perceptions of genomic sequencing uses in critical cardiac disease appear to strain their overall trust in the health system. Erosion of trust is concerning because the potential of genomic sequencing in critical cardiac disease will be unrealized if families are unwilling to undergo genomic sequencing, let alone to participate in the ongoing research needed to link genomic sequencing variants to clinical outcomes. Our findings may have implications for genomic sequencing use in children with other critical, high-acuity diseases.
Authors: Laurel K Willig; Josh E Petrikin; Laurie D Smith; Carol J Saunders; Isabelle Thiffault; Neil A Miller; Sarah E Soden; Julie A Cakici; Suzanne M Herd; Greyson Twist; Aaron Noll; Mitchell Creed; Patria M Alba; Shannon L Carpenter; Mark A Clements; Ryan T Fischer; J Allyson Hays; Howard Kilbride; Ryan J McDonough; Jamie L Rosterman; Sarah L Tsai; Lee Zellmer; Emily G Farrow; Stephen F Kingsmore Journal: Lancet Respir Med Date: 2015-04-27 Impact factor: 30.700
Authors: Sara M Fitzgerald-Butt; Jennifer Klima; Kelly Kelleher; Deena Chisolm; Kim L McBride Journal: Am J Med Genet A Date: 2014-09-24 Impact factor: 2.802
Authors: Jan M Friedman; Yvonne Bombard; Martina C Cornel; Conrad V Fernandez; Anne K Junker; Sharon E Plon; Zornitza Stark; Bartha Maria Knoppers Journal: Genet Med Date: 2018-06-12 Impact factor: 8.822
Authors: Dana B Gal; Ana Morales; Susan Rojahn; Tom Callis; John Garcia; James R Priest; Rebecca Truty; Matteo Vatta; Robert L Nussbaum; Edward D Esplin; Seth A Hollander Journal: Pediatr Cardiol Date: 2021-10-29 Impact factor: 1.655